EMI

Encore Medical, Inc. develops, manufactures, and markets septal occlusion devices for the repair of certain cardiac defects. The Company’s septal occlusion devices are small, implantable devices that are positioned and delivered through a catheter inserted into a major blood vessel (typically via femoral venous access) to repair certain cardiac defects in both adults and children. These closure devices are capable of providing an effective, nonsurgical method of correcting a variety of cardiac defects. Its primary closure device is designed to correct a cardiac defect, generally diagnosed in adulthood, known as a patent foramen ovale (PFO).The PFO defect is an abnormal passage or flap-like hole between the atrial chambers of the heart that can enable embolic material (clots) to travel from the right to left chambers and potentially cause a stroke. It also markets and sells septal occlusion devices for the transcatheter closure of atrial septal defects (ASD).